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Objective: To determine the effect of a community
pharmacist prescribing intervention on glycaemic control
in patients with poorly controlled type 2 diabetes.
Design: Pragmatic, before–after design.
Setting: 12 community pharmacies in Alberta, Canada.
Participants: Type 2 diabetes receiving oral
hypoglycaemic medications and with glycated
haemoglobin (HbA1c) of 7.5–11%.
Intervention: Pharmacists systematically identified
potential candidates by inviting patients with type 2
diabetes to test their HbA1c using validated point-of-care
technology. Pharmacists prescribed 10 units of insulin
glargine at bedtime, adjusted by increments of 1 unit daily
to achieve a morning fasting glucose of ≤5.5 mmol/L. The
patients were followed up at 2, 4, 8, 14, 20 and 26 weeks.
Primary outcome: Change in HbA1c from baseline to
week 26.
Secondary outcomes: Proportion of patients achieving
target HbA1c, changes in oral hypoglycaemic agents,
quality of life and patient satisfaction, persistence on
insulin glargine, number of insulin dosage adjustments
per patient and number of hypoglycaemic episodes.
Results:We screened 365 patients of whom 111 were
eligible. Of those, 100 (90%) were enrolled in the study; all
11 patients who did not consent refused to use insulin.
Average age was 64 years (SD 10.4), while average
diabetes duration was 10.2 years (SD 7). HbA1c was
reduced from 9.1% (SD 1) at baseline to 7.3% (SD 0.9); a
change of 1.8% (95% CI 1.4 to 2, p<0.001). Fasting
plasma glucose was reduced from 11 (SD 3.3) to
6.9 mmol/L (SD 1.8); a change of 4.1 mmol/L (95% CI of
3.3 to 5, p=0.007). Fifty-one per cent of the patients
achieved the target HbA1c of ≤7% at the end of the study.
Conclusions: This is the first completed study of
independent prescribing by pharmacists. Our results
showed similar improvements in glycaemic control as
previous physician-led studies. RxING provides further
evidence for the benefit of pharmacist care in diabetes.
Trial registration: clinicaltrials.gov; Identifier:
NCT01335763.
INTRODUCTION
Currently, 347 million individuals are living
with diabetes worldwide.1 Approximately 90%
of them have type 2 diabetes.1 The number of
new cases of type 2 diabetes is rapidly increas-
ing mainly because of obesity and an ageing
population.2
Because of its chronic nature and the
severe complications associated with it, dia-
betes carries a health and a financial burden
on the affected individual and health
systems.3 Poorly controlled diabetes puts
patients at high risk of suffering from macro-
vascular and microvascular complications.4
Type 2 diabetes is a progressive disease; it
has been reported that 50% of the insulin-
producing capacity is lost at the time of diag-
nosis with an average loss rate of 5% per year
afterwards.5 As a result, many patients with
type 2 diabetes will eventually require the
use of insulin; however, clinicians seem reluc-
tant to start insulin6 despite evidence from
studies such as INSIGHT, which demon-
strated improved glycaemic control with the
addition of insulin glargine to oral hypogly-
caemic agents in patients with type 2 dia-
betes7 as well as guidelines that recommend
ARTICLE SUMMARY
Strengths and limitations of the study
▪ This is the first study of independent prescribing
by pharmacists in patients with diabetes and it
demonstrates a clinically important improvement
in glycaemic control.
▪ The 26-week follow-up period can be considered
relatively short; it is possible that with a longer
study more patients may have achieved the
target glycated haemoglobin (or fewer if patients
discontinued their insulin).
▪ We did observe several ‘hypoglycaemic-type
symptoms’, however we were not able to
confirm these as true hypoglycaemia. We also
have no frame of reference as patients may have
experienced some of these symptoms prior to
enrolling in our study. Finally, the number of
reported ‘hypoglycaemic-type symptoms’ in this
study was consistent with the findings reported
in the literature.
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starting insulin immediately if the patient’s glycated
haemoglobin (HbA1c) is ≥9%.8
Clinicians’ reluctance to initiate insulin due to
unfamiliarity with the treatment or using it as a last
resort9 plays a major role in influencing the patient’s
decision to start insulin treatment regimen. It has been
reported that many patients have ‘psychological insulin
resistance’ where they are unwilling to take insulin
because of certain beliefs that insulin will not be benefi-
cial and in some cases it may even be harmful. Personal
experience and messages from different healthcare
professionals can also affect the patient’s decisions
regarding insulin treatment regimen.6 10
Pharmacists are front line healthcare professionals who
see patients with diabetes more frequently than physicians
(15 vs 7 times/year)11 and as such, could proactively and
systematically identify patients with poorly controlled type 2
diabetes in a broad-based public health approach to
chronic disease management.12 Indeed, there is good evi-
dence for the efficacy of pharmacist care in diabetes.13 In
community settings, pharmacists have demonstrated that
they are capable of identifying poorly controlled patients,
educate patients regarding diabetes, medications and self-
monitoring of plasma glucose, provide adherence support,
identify and resolve diabetes problems and complications
and setting goals to reduce the patients’ HbA1c, plasma
glucose and improve their quality of life and other
comorbidities.4 12–16 Moreover, the scope of practice for
pharmacists in Alberta is changing, allowing pharmacists to
prescribe medications and order laboratory tests. As such,
there is an unprecedented opportunity to identify and
improve glycaemic control in patients with type 2 diabetes.
The main aim of the RxING study was to determine
the effect of a community pharmacist prescribing inter-
vention on glycaemic control in patients with poorly
controlled type 2 diabetes.
METHODS
Study design and setting
RxING was a multicentre pragmatic before–after design
trial, which was conducted in 12 community pharmacies
in the province of Alberta, Canada.
We chose the before–after design because we had con-
cerns about withholding insulin from this high-risk group.
The concerns were based on guidelines recommenda-
tions8 and the evidence from studies such as INSIGHT.7
All participating pharmacists, who were either certified
diabetes educators (CDE) or preparing to be CDE,
received face-to-face training by the study team. The
training material was based on the most recent
Canadian guidelines and recommendations.7 8 They also
received a manual of operations to help them conduct
the study.
Study participants
We recruited adults who had physician diagnosed type 2
diabetes for at least 6 months and were receiving one or
more oral hypoglycaemic agents, had an HbA1c
between 7.5% and 11% and who were willing to sign an
informed consent.
We excluded patients who were unwilling to use
insulin, previously or currently using insulin (confirmed
by the patient’s medication records), had a history of
ketoacidosis (confirmed by the patient’s healthcare
records), were pregnant, worked night shifts, had renal
impairment (serum creatine of ≥ 124 mmol/L for
females or ≥ 133 mmol/L for males; confirmed by the
patient’s healthcare records), were clinically unstable
(based on the pharmacist’s judgement), were unwilling
or unable to attend follow-up visits or felt to be unlikely
to adhere to study procedures due to cognitive limita-
tions (based on the pharmacist’s judgement), severe psy-
chiatric disorders or alcoholism (confirmed by the
patient’s healthcare records).
Recruitment
Pharmacists systematically identified potential candidates
from within their practice by inviting patients with type
2 diabetes (eg, patients on metformin) to test their
HbA1c in the pharmacy using validated point of care
technology (DCA Vantage, Siemens, Tarrytown,
New York, USA). If the result of the HbA1c test was high
(7.5–11%) and the patient met the other inclusion cri-
teria for the study the patient was asked if he/she
wanted to participate in the study. After providing
written informed consent, the patient was enrolled in
the study. If HbA1c was > 11% the patient was assessed
by the study investigators and the patient was referred to
his/her physician.
Intervention
The patient was prescribed 10 units insulin glargine at
bedtime and was asked to titrate the dose by 1 unit/day to
achieve a fasting plasma glucose (FPG) of ≤ 5.5 mmol/L.7 17
The intervention also included patient education regarding
insulin use, dose titration and self-monitoring. Patients con-
tacted the pharmacist when they reached a FPG of
6 mmol/L. All patients remained on their previously pre-
scribed oral hypoglycaemic agent(s). If the combination
with insulin was not approved in Canada, the oral hypogly-
caemic agent was discontinued (eg, thiazolidinedione).
Adjustments were made at the discretion of the treating
pharmacist based on the most recent Canadian guidelines.8
The patient’s family physician received a letter from the
pharmacist to inform him/her that the patient was partici-
pating in the study.
Follow-up
Patients were followed at 2, 4, 8, 14, 20 and 26 weeks to
provide ongoing care, check adherence to the insulin
regimen, fasting blood sugars (measured by the
patient), insulin dose and titration and adverse events.
HbA1c was measured at weeks 14 and 26 using the same
technique used at baseline. Family physicians were kept
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informed of patient’s progress and any medication
change after each visit.
Outcomes
The primary outcome measure was the change in HbA1c
from baseline to week 26. Secondary outcomes included
proportion of patients achieving target HbA1c (defined
as HbA1c ≤ 7.0%), changes in oral hypoglycaemic
agents, quality of life and patient satisfaction using Audit
of Diabetes—Dependent Quality of Life (ADDQoL),
Diabetes Treatment Satisfaction Questionnaire (DTSQ)
and Diabetes Treatment Satisfaction (Change)
Questionnaire (DTSQc), persistence on insulin glargine
(% still taking insulin at the end of follow-up), number of
insulin dosage adjustments per patient, number of hypo-
glycaemic episodes.
Sample size calculation
With a sample size of 80 patients and the following
assumptions, an SD of 1.1 and a two-sided α of 0.05,7 we
calculated 90% power to detect a mean decrease in
HbA1c of 0.4%. Since this a pragmatic, practice-based
trial, the sample size was inflated to 100 to account for
possible losses to follow-up.
Data analysis
The level of significance was set at 0.05. All analyses
were performed on intention to treat basis. Missing data
Figure 1 Patients’ screening and enrolment flow chart.
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were imputed using a last value carried forward strategy.
The mean HbA1c between baseline and 26 weeks was
compared using paired t test. Secondary outcomes were
analysed using paired t tests and basic frequencies.
Linear regression was used to adjust for the patients’
demographics and clinical characteristics.
RESULTS
We screened 356 patients with type 2 diabetes; 245 were
excluded because they did not meet the HbA1c inclu-
sion criteria. Of the 111 eligible patients, 11 were not
enrolled because they refused to use insulin, leaving 100
patients enrolled (figure 1).
The demographic and clinical characteristics of the
patients are reported in table 1. Patients’ mean age was
64 years (SD 10.4) and had a diabetes duration of
10.2 years (SD 7). Fifty-eight per cent of the patients were
men, 77% were married and 90% reported having at
least high school education. Nearly half of the patients
(48%) were retired, almost ninety per cent (89%) were
white (ethnicity was self-reported) and nearly half (47%)
have a government medication coverage. Around one-
quarter of the patients (22%) reported that they were
smokers and more than half (54%) reported occasional
consumption of alcohol (eg, 1–3 drinks/week). Nearly
two-thirds of the patients had elevated blood pressure
(63%) and elevated cholesterol (64%; hypertension and
high cholesterol were self-reported).
All but one patient was taking insulin glargine at the
end of the study (he stopped his insulin before the final
visit because his plasma glucose readings were ‘good’).
At the end of the study the mean insulin glargine dose
was 31.1 units (SD 18.4) with a mean of 21.1 dose adjust-
ments (SD 18.8) per patient.
HbA1c was reduced from 9.1% (SD 1) at baseline to
7.3% (SD 0.9) at 26 weeks, a change of 1.8% (95% CI
1.4 to 2, p<0.001; figure 2),. whereas FPG was reduced
from 11 mmol/L (SD 3.3) at baseline to 6.9 mmol/L
(SD 1.8) at 26 weeks, a change of 4.1 mmol/L (95% CI
of 3.3 to 5, p=0.007; figure 3).
Fifty-one per cent of the patients achieved the target
HbA1c of ≤7% at the end of the study. At baseline,
two-thirds (66%) of the patients were taking two or
more medications (table 2), the most widely used com-
bination was metformin and gliclazide, followed by met-
formin and glyburide and metformin and repaglinide.
Nearly half of the patients (48%) had their oral hypogly-
caemic regimen altered (table 3); the most frequent
alterations were stopping sulfonylurea (46%) followed
by initiating meglitinides (23%), stopping metformin
(21%) and stopping thiazolidinedoine and dipeptidyl
peptidase 4 inhibitors (19%). Those alterations were
made by the pharmacists who then informed the
patients’ family physicians.
Only 40% of the patients returned quality-of-life and
treatment satisfaction questionnaires. Of those, only
30 questionnaires were analysable. Quality of life and
treatment satisfaction have improved by 0.2 and 3.5,
respectively among the patients who returned the
questionnaires.
Figure 2 Intervention effect on glycated haemoglobin in
patients with uncontrolled type 2 diabetes (n=100).
Figure 3 Intervention effect on fasting plasma glucose in
patients with uncontrolled type 2 diabetes (n=100).
Table 2 Number of oral hypoglycaemic agents used by
patients and mean glycated haemoglobin (HbA1c)
Number of oral agents Frequency Mean HbA1c (SD)
1 34 8.7 (0.9)
2 56 9.1 (0.9)
3 7 9.8 (1.6)
4 3 8.7 (0.7)
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Body mass index was 31.6 (SD 6.3) at baseline and
32.6 (SD 6.3) at the end of follow-up (p=0.29) and waist
circumference was 106 cm (SD 13.8) at baseline and
107.4 cm (SD 12.9) at the end of follow-up (p=0.5).
‘Hypoglycaemic-type’ symptoms were reported by 54
patients. Only two of these episodes required medical
attention (one caused a visit to the family physician
while the other required a visit to the emergency depart-
ment without an overnight stay). We were neither able
to confirm whether these episodes were true hypogly-
caemia, through blood glucose measurements, nor did
we have baseline information on such symptoms.
DISCUSSION
We found that a community pharmacist prescribing
intervention in patients with poorly controlled type 2
diabetes improved patients’ HbA1c by an absolute value
of 1.8% (95% CI 1.4 to 2, p<0.001) and FPG by
4.1 mmol/L (95% CI of 3.3 to 5, p=0.007). This is the
first study of independent prescribing by pharmacists in
patients with diabetes and represents a clinically import-
ant improvement in glycaemic control.
Our findings are consistent with the findings of
Gerstein et al7 and Harris et al 9 who compared the effect
of adding insulin glargine to the oral hypoglycaemic
regimen versus the conventional therapy where oral
hypoglycaemic agent doses were adjusted. They reported
better glycaemic control in the insulin glargine group
after 26 weeks of follow-up. Our findings are also consist-
ent with the findings of Wubben and Vivian13 who con-
ducted a systematic review to assess the effectiveness of
pharmacist intervention in patients with diabetes in out-
patient settings. They reported additional HbA1c reduc-
tion (when compared to usual care) of 0.5% when
pharmacists did not have prescribing authority and 1%
when pharmacists had prescribing authority (collabora-
tive prescribing in this case).
It has been reported in the literature that the adher-
ence rates to the insulin regimen are unsatisfactory18;
however in our study, 99% of the patients were adherent
to their treatment regimen for 6 months. This can be
explained by the intensive intervention provided by the
pharmacist and the relatively short duration of the study.
This study is not without limitations. The 26-week
follow-up period can be considered relatively short; it is
possible that with a longer study more patients may have
achieved the target HbA1c (or fewer if patients discon-
tinued their insulin). Patients who were unwilling to use
insulin were excluded from the study; however, patients’
willingness to use insulin was high in our pilot study4
and also during the screening process. The proactive
and systematic approach that we used in this study also
helped in identifying patients who could benefit from
insulin. We acknowledge that adding insulin to the oral
hypoglycaemic agent(s) regimen is one of the options
that are available to improve glycaemic control; however,
this choice was based on the insulin’s efficacy and safety
profile. The response rate to quality-of-life and treat-
ment satisfaction questionnaires was low; however, the
improvements in quality of life and treatment satisfac-
tions are consistent with the findings of Gerstein et al7
who reported improvements in treatment satisfaction in
the insulin glargine group. We also received unsolicited
comments from different patients highlighting their
pleasure and satisfaction with treatment and its impact
on their daily activities.
We did observe several ‘hypoglycaemic-like’ symptoms;
however, we were not able to confirm these as true hypo-
glycaemia. We also have no frame of reference as
patients may have experienced some of these symptoms
prior to enrolling in our study. Finally, the number of
reported ‘hypoglycaemic-type symptoms’ in this study
was consistent with the findings of a meta-analysis of
more than 1100 diabetes patients who were using insulin
glargine.19
Our findings take the evidence for the benefits of
pharmacist care in diabetes one step further. That pre-
scribing insulin improves glycaemic control in itself is
perhaps not surprising; what is important is that pharma-
cists can systematically identify patients with poor
glycaemic control, educate and support patients to
achieve better outcomes. Since pharmacists see patients
with diabetes frequently,11 this can be an attractive
approach.
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